Enjoy complimentary customisation on priority with our Enterprise License!
The HDAC (histone deacetylase) inhibitors market is estimated to increase by USD 172.61 million between 2022 and 2027. The size of the market is forecast to grow at a CAGR of 7.73%. The growth of the market depends on several factors, including high target affinity and specificity, high prevalence of oncology indications, and the development of novel drug delivery systems and combination therapies.
To learn more about this report, Download Report Sample
The high target affinity and specificity are notably driving the market growth, although factors such as high costs associated with treatment may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Driver
The high target affinity and specificity is one of the key drivers supporting the market growth. HDAC inhibitors are known to demonstrate promising results in cancer treatments, which is further promotes the R&D teams to conduct research for other applications such as neurologic conditions. These inhibitors have the quality of inducing differentiation, cell-cycle arrest, and apoptosis.
Furthermore, they inhibit migration, invasion, and angiogenesis in many cancer cell lines. Unlike conventional therapies, these drugs work directly on the target, and hence, their efficacy is higher than the conventional treatments. The mechanism of action (MoA) of this drug class is target-specific, which makes it a potential single solution for many diseases, including neurological disorders and carcinomas, among both medical practitioners as well as patients, which drives the market growth.
Significant Trend
Growing awareness about cancer is the primary trend in the market. Various international and national-level campaigns are conducted to increase awareness about cancer and help early detection of the disease. For instance, organizations such as the American Social Health Association (ASHA) and the National Cervical Cancer Coalition (NCCC) implement initiatives to create awareness about the prevention and control of cervical cancer. Similarly, the CDC provides guidelines and conducts awareness programs to screen and vaccinate underserved individuals with cervical cancer.
Furthermore, Cancer Breakthroughs 2020, previously known as Cancer Moonshot 2020, is an initiative taken by the US government in 2016 for the development of research on vaccine-based immunotherapies to fight cancer. The aim of this project is to make therapies available to more patients while detecting the disease at an early stage. By inviting the pharmaceutical players to join the initiative, the Cancer Breakthroughs 2020 program plans on making the targeted therapies one of the major areas of focus of this project. These initiatives are expected to increase awareness about cancer and the available treatments, including various targeted and immunotherapies treating cancer during the forecast period.
Major Challenge
High costs associated with treatment is one of the factors hindering the market growth. Many HDAC inhibitors are used in combination with substitutes such as surgery and radiation therapies, which increases the cost burden of the treatment significantly. The high cost of cancer treatment is mainly due to hospitalization, laboratory tests, and novel therapies. In developing and underdeveloped countries, the cost of treatment with HDAC inhibitors is very high.
For instance, belinostat (BELEODAQ) costs around USD1,976.75 for one unit of 500 mg of powder for injection. Also, according to the CDC, the cost of cancer care continues to rise and is expected to reach almost USD174 billion by 2020. Such high treatment costs act as a barrier to drug adoption, which reduces the patient base and poses a challenge to market growth.
Key Market Customer Landscape
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Onxeo SA - Onxeo SA is a public company that is headquartered in France. It is a regional company that generated a revenue of USD 12.13 million and had around 25 employees. Its revenue from the global histone deacetylase (HDAC) inhibitors market contributes to its overall revenues, along with its other offerings, but is not a key revenue stream for the company. The company offers farydak deacetylase inhibitor which is used to treat multiple myeloma cancer treatment.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market players, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth of the oral HDAC inhibitors segment will be significant during the forecast period. The strong pipeline of oral HDAC inhibitors is the major factor driving the growth of the segment. This type of HDAC inhibitor is taken orally or through the mouth. Currently, more than ten HDAC inhibitors, which can be administered through oral RoA, are in the pipeline. The presence of such a strong pipeline will aid in the launch of new drugs for administration via the oral route during the forecast period, which will increase the product portfolio of the oral HDAC inhibitors segment. This, in turn, will result in market growth.
Get a glance at the market contribution of various segments Request a PDF Sample
The oral HDAC inhibitors segment was valued at USD 230.76 million in 2017 and continued to grow until 2021. The oral route is the easiest way to administer a drug. However, the cost of these drugs is very high. Therefore, to overcome the high-cost challenge of these drugs, many companies and government or non-government organizations are providing financial assistance through patient assistance programs. Therefore, a strong pipeline coupled with the availability of patient assistance programs is expected to drive the growth of the segment.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 32% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The high prevalence of cancer and the increasing need for innovative medications are the major factors driving the market growth in this region. Although the US has several approved therapies, various side effects associated with most of them create a huge demand for enhanced therapies. Hence, HDAC inhibitors are attracting extensive R&D attention in the country due to their target-specific treatment approach. These extensive R&D efforts get further support from an established R&D platform and the presence of all major oncology vendors in the country, resulting in a strong pipeline. Currently, a few molecules are in the late stages of development. Hence, late-stage molecules in the pipeline are expected to be launched during the forecast period, which will expand the product portfolio in the market and drive market growth in the region.
Many pharmaceutical companies are headquartered in the US, thus making it a hub for the pharmaceutical industry, which further strengthens the drug distribution network in the country. Hence, the US is the strongest player in the market, and the majority of the market share of North America is attributed to the country, thus resulting in fast saturation of the market. Hence, the HDAC inhibitors market in North America is growing at a lower CAGR than the global market.
The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
The market is segmented based on classification into Class I HDACs, Class II HDACs, Class III HDACs, and Others. The route of Administration includes Oral, Injectable, and Others, with End Users being Hospitals, home care, Specialty Clinics, and Others. Distribution Channels encompass Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others. The market focuses on Targeted modes of therapies, Novel drugs, and therapies, with a prevalent concern for chronic disorders and Anti-cancer agents. It includes Chemotherapy agents, T-cell lymphoma, and considerations for Personal disposable income. Market growth rates, Trade regulations, Import-export analyses, and Production analyses are key components, along with Value chain optimization and the Impact of domestic and localized market players.
Market regulations and Strategic market growth analyses are integral, along with Category market growths, Application niches, and Product launches. Insights into Market overview, Strategic decisions, Identification of core market applications, and Patient Epidemiology Analysis are crucial. This includes Incidence, Mortality, and Adherence rates. Some of the major vendors in the market include Crystal Genomics Inc, Shenzhen Chipscreen Biosciences Co, Spectrum Pharmaceuticals, Inc, Merck & Co, FORUM Pharmaceuticals Inc, Eisai Co, REGENACY PHARMACEUTICALS, INC, Karyopharm, Aurobindo Pharma, CARDIFF ONCOLOGY, Wellness Pharma International, and MEI Pharma, Inc.
HDAC (Histone Deacetylase) Inhibitors Market Scope |
|
Report Coverage |
Details |
Page number |
157 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.73% |
Market growth 2023-2027 |
USD 172.61 million |
Market structure |
Concentrated |
YoY growth 2022-2023(%) |
6.74 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 32% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Acrotech Biopharma Inc., AstraZeneca Plc, Bio Techne Corp., BioVision Inc., Bristol Myers Squibb Co., Celleron Therapeutics Ltd., Curis Inc., Huya Bioscience International LLC, InvivoGen Corp., Italfarmaco Spa, Medivir AB, Merck and Co. Inc., Novartis AG, Onxeo SA, Shenzhen Chipscreen Biotechnology Co. Ltd., Syndax Pharmaceuticals Inc., Tokyo Chemical Industry Co. Ltd., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd., and Cetya Therapeutics Inc. |
Market dynamics |
Parent market analysis, Market forecasting, market growth and trends, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our market research report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.